



## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the Application of:

SCIALDONE ET AL

CASE NO.: CL1723 US NA

APPLICATION NO.: 10/074,389

GROUP ART UNIT: 1653

FILED: FEBRUARY 12, 2002

EXAMINER: MAYES, L.

FOR: ANGIOGENESIS-INHIBITORY TRIPEPTIDES,  
COMPOSITIONS AND THEIR METHODS OF USE**REPLY AND AMENDMENT**Assistant Commissioner for Patents  
Alexandria, VA 22313

Sir:

This reply is in response to the non-final Office Action (Paper 5) dated 11 December 2002. A two-month extension of time for reply is enclosed herewith. Please enter the following amendments and remarks:

**In The Claims:**

Please amend the claims as follows:

1. (Amended One Time) An angiogenesis-inhibitory tripeptide of formula aa1-aa2-aa3, having a first amino acid (aa1), a second amino acid (aa2) and a third amino acid (aa3), wherein:
  - (a) said first amino acid is selected from the group consisting of Ser, Thr, Ala, Phe, Tyr, Cys, Gly, Leu, Lys, Pro, Arg, Gln, Glu, Asp, Asn, His, Met, Ile, Trp, Val, diaminopropionic acid and *trans*-4-hydroxy-proline;
  - (b) said second amino acid is selected from the group consisting of Asn, Ala, Gly, Asp, Glu, Gln diaminopropionic acid and *trans*-4-hydroxy-proline; and
  - (c) said third amino acid is selected from the group consisting of Ser, Thr, Ala, Phe, Tyr, Cys, Gly, Leu, Lys, Pro, Arg, Gln, Glu, Asp, Asn, His, Met, Ile, Trp, Val, diaminopropionic acid and *trans*-4-hydroxy-proline;and wherein the tripeptide is not Arg-Gly-Asp.